Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages

Key Points

• Seven brokerages give Zentalis an average rating of Hold (1 sell, 4 hold, 1 buy, 1 strong buy) with a mean 12‑month price target of $5.83; notable calls include Guggenheim raising its target to $10 and Wells Fargo setting an "equal weight" $5 target.
• Insider Vincent Vultaggio sold 29,951 shares (part of 46,617 shares sold by insiders this quarter), while institutions such as 5AM Venture, Millennium, Vanguard and Renaissance materially increased stakes (5AM up 705.7% to ~3.95M shares), indicating mixed insider selling but significant institutional accumulation.
• Shares trade in a 1‑year range of $1.09–$6.95 with a market cap of ~$469M; Zentalis reported a $0.49 loss per share last quarter (miss) and projects ~‑2.42 EPS for the year, while its lead candidate ZN‑c3 is in Phase I trials for oncology.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been given an average rating of "Hold" by the seven brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $5.8333.

A number of research analysts have commented on the stock. Guggenheim raised their target price on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a "buy" rating in a research report on Friday. Weiss Ratings reissued a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a research report on Tuesday, April 7th. Wall Street Zen downgraded shares of Zentalis Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, March 28th. Finally, Wells Fargo & Company assumed coverage on shares of Zentalis Pharmaceuticals in a research report on Tuesday, March 17th. They set an "equal weight" rating and a $5.00 target price on the stock.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, insider Vincent Vultaggio sold 29,951 shares of the firm's stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $2.43, for a total transaction of $72,780.93. Following the transaction, the insider owned 156,779 shares of the company's stock, valued at approximately $380,972.97. This trade represents a 16.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 46,617 shares of company stock worth $113,417. Company insiders own 1.90% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. 5AM Venture Management LLC increased its position in Zentalis Pharmaceuticals by 705.7% during the 4th quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company's stock valued at $5,330,000 after purchasing an additional 3,457,913 shares during the period. Millennium Management LLC grew its position in shares of Zentalis Pharmaceuticals by 220.6% in the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company's stock worth $4,881,000 after buying an additional 2,111,951 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Zentalis Pharmaceuticals by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company's stock worth $4,386,000 after buying an additional 19,768 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Zentalis Pharmaceuticals by 24.0% in the 4th quarter. Renaissance Technologies LLC now owns 2,883,745 shares of the company's stock worth $3,893,000 after buying an additional 558,390 shares during the last quarter. Finally, Bank of America Corp DE grew its position in shares of Zentalis Pharmaceuticals by 117.1% in the 3rd quarter. Bank of America Corp DE now owns 1,548,781 shares of the company's stock worth $2,339,000 after buying an additional 835,466 shares during the last quarter.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL opened at $6.61 on Monday. Zentalis Pharmaceuticals has a 1-year low of $1.09 and a 1-year high of $6.95. The company has a 50-day moving average of $2.63 and a 200 day moving average of $2.06. The firm has a market capitalization of $468.85 million, a price-to-earnings ratio of -3.48 and a beta of 1.65.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.08). On average, equities analysts anticipate that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.